Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.

@article{Ruxrungtham2004LackOI,
  title={Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.},
  author={Kiat Ruxrungtham and Mark Boyd and S Eralp Bellibas and Xiaoping Zhang and Albert E. Dorr and Stanley J Kolis and Tosca Kinchelow and Neil Buss and Indravadan H. Patel},
  journal={Journal of clinical pharmacology},
  year={2004},
  volume={44 7},
  pages={793-803}
}
Enfuvirtide (Fuzeon) is an HIV fusion inhibitor, the first drug in a new class of antiretrovirals. The HIV protease inhibitors ritonavir and saquinavir both inhibit cytochrome P450 (CYP450) isoenzymes, and low-dose ritonavir is often used to boost pharmacokinetic exposure to full-dose protease inhibitors. These two studies were designed to assess whether ritonavir and ritonavir-boosted saquinavir influence the steady-state pharmacokinetics of enfuvirtide. Both studies were single-center, open… CONTINUE READING

Similar Papers

Loading similar papers…